King's College London

Research portal

A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: Results at the 36-month follow-up

Research output: Contribution to journalArticle

Standard

A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease : Results at the 36-month follow-up. / Jost, Stefanie Theresa; Sauerbier, Anna; Sauerbier, Anna; Visser-Vandewalle, Veerle; Ashkan, Keyoumars; Silverdale, Monty; Evans, Julian; Loehrer, Philipp A.; Rizos, Alexandra; Petry-Schmelzer, Jan Niklas; Reker, Paul; Fink, Gereon Rudolf; Franklin, Jeremy; Samuel, Michael; Schnitzler, Alfons; Barbe, Michael Thomas; Antonini, Angelo; Antonini, Angelo; Martinez-Martin, Pablo; Timmermann, Lars; Ray-Chaudhuri, K.; Ray-Chaudhuri, K.; Dafsari, Haidar S.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 91, No. 7, 01.07.2020, p. 687-694.

Research output: Contribution to journalArticle

Harvard

Jost, ST, Sauerbier, A, Sauerbier, A, Visser-Vandewalle, V, Ashkan, K, Silverdale, M, Evans, J, Loehrer, PA, Rizos, A, Petry-Schmelzer, JN, Reker, P, Fink, GR, Franklin, J, Samuel, M, Schnitzler, A, Barbe, MT, Antonini, A, Antonini, A, Martinez-Martin, P, Timmermann, L, Ray-Chaudhuri, K, Ray-Chaudhuri, K & Dafsari, HS 2020, 'A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: Results at the 36-month follow-up', Journal of Neurology, Neurosurgery and Psychiatry, vol. 91, no. 7, pp. 687-694. https://doi.org/10.1136/jnnp-2019-322614

APA

Jost, S. T., Sauerbier, A., Sauerbier, A., Visser-Vandewalle, V., Ashkan, K., Silverdale, M., Evans, J., Loehrer, P. A., Rizos, A., Petry-Schmelzer, J. N., Reker, P., Fink, G. R., Franklin, J., Samuel, M., Schnitzler, A., Barbe, M. T., Antonini, A., Antonini, A., Martinez-Martin, P., ... Dafsari, H. S. (2020). A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: Results at the 36-month follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 91(7), 687-694. https://doi.org/10.1136/jnnp-2019-322614

Vancouver

Jost ST, Sauerbier A, Sauerbier A, Visser-Vandewalle V, Ashkan K, Silverdale M et al. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: Results at the 36-month follow-up. Journal of Neurology, Neurosurgery and Psychiatry. 2020 Jul 1;91(7):687-694. https://doi.org/10.1136/jnnp-2019-322614

Author

Jost, Stefanie Theresa ; Sauerbier, Anna ; Sauerbier, Anna ; Visser-Vandewalle, Veerle ; Ashkan, Keyoumars ; Silverdale, Monty ; Evans, Julian ; Loehrer, Philipp A. ; Rizos, Alexandra ; Petry-Schmelzer, Jan Niklas ; Reker, Paul ; Fink, Gereon Rudolf ; Franklin, Jeremy ; Samuel, Michael ; Schnitzler, Alfons ; Barbe, Michael Thomas ; Antonini, Angelo ; Antonini, Angelo ; Martinez-Martin, Pablo ; Timmermann, Lars ; Ray-Chaudhuri, K. ; Ray-Chaudhuri, K. ; Dafsari, Haidar S. / A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease : Results at the 36-month follow-up. In: Journal of Neurology, Neurosurgery and Psychiatry. 2020 ; Vol. 91, No. 7. pp. 687-694.

Bibtex Download

@article{b1d5f280b68f4010938a812dc5b63e12,
title = "A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: Results at the 36-month follow-up",
abstract = "Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson's disease (PD). Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination,-activities of daily living, and-complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen's effect size. In addition, bivariate correlations of change scores were explored. Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and-complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly. Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments. ",
author = "Jost, {Stefanie Theresa} and Anna Sauerbier and Anna Sauerbier and Veerle Visser-Vandewalle and Keyoumars Ashkan and Monty Silverdale and Julian Evans and Loehrer, {Philipp A.} and Alexandra Rizos and Petry-Schmelzer, {Jan Niklas} and Paul Reker and Fink, {Gereon Rudolf} and Jeremy Franklin and Michael Samuel and Alfons Schnitzler and Barbe, {Michael Thomas} and Angelo Antonini and Angelo Antonini and Pablo Martinez-Martin and Lars Timmermann and K. Ray-Chaudhuri and K. Ray-Chaudhuri and Dafsari, {Haidar S.}",
year = "2020",
month = jul,
day = "1",
doi = "10.1136/jnnp-2019-322614",
language = "English",
volume = "91",
pages = "687--694",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group Ltd",
number = "7",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease

T2 - Results at the 36-month follow-up

AU - Jost, Stefanie Theresa

AU - Sauerbier, Anna

AU - Sauerbier, Anna

AU - Visser-Vandewalle, Veerle

AU - Ashkan, Keyoumars

AU - Silverdale, Monty

AU - Evans, Julian

AU - Loehrer, Philipp A.

AU - Rizos, Alexandra

AU - Petry-Schmelzer, Jan Niklas

AU - Reker, Paul

AU - Fink, Gereon Rudolf

AU - Franklin, Jeremy

AU - Samuel, Michael

AU - Schnitzler, Alfons

AU - Barbe, Michael Thomas

AU - Antonini, Angelo

AU - Antonini, Angelo

AU - Martinez-Martin, Pablo

AU - Timmermann, Lars

AU - Ray-Chaudhuri, K.

AU - Ray-Chaudhuri, K.

AU - Dafsari, Haidar S.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson's disease (PD). Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination,-activities of daily living, and-complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen's effect size. In addition, bivariate correlations of change scores were explored. Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and-complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly. Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments.

AB - Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in Parkinson's disease (PD). Methods Here we report the 36-month follow-up of a prospective, observational, controlled, international multicentre study of the NILS cohort. Assessments included NMSScale (NMSS), PDQuestionnaire-8 (PDQ-8), Scales for Outcomes in PD (SCOPA)-motor examination,-activities of daily living, and-complications, and levodopa equivalent daily dose (LEDD). Propensity score matching resulted in a pseudo-randomised sub-cohort balancing baseline demographic and clinical characteristics between the STN-DBS and MED groups. Within-group longitudinal outcome changes were analysed using Wilcoxon signed-rank and between-group differences of change scores with Mann-Whitney U test. Strength of clinical responses was quantified with Cohen's effect size. In addition, bivariate correlations of change scores were explored. Results Propensity score matching applied on the cohort of 151 patients (STN-DBS n=67, MED n=84) resulted in a well-balanced sub-cohort including 38 patients per group. After 36 months, STN-DBS significantly improved NMSS, PDQ-8, SCOPA-motor examination and-complications and reduced LEDD. Significant between-group differences, all favouring STN-DBS, were found for NMSS, SCOPA-motor complications, LEDD (large effects), motor examination and PDQ-8 (moderate effects). Furthermore, significant differences were found for the sleep/fatigue, urinary (large effects) and miscellaneous NMSS domains (moderate effects). NMSS total and PDQ-8 change scores correlated significantly. Conclusions This study provides Class IIb evidence for beneficial effects of STN-DBS on NMS at 36-month follow-up which also correlated with quality of life improvements. This highlights the importance of NMS for DBS outcomes assessments.

UR - http://www.scopus.com/inward/record.url?scp=85086694514&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2019-322614

DO - 10.1136/jnnp-2019-322614

M3 - Article

C2 - 32371534

AN - SCOPUS:85086694514

VL - 91

SP - 687

EP - 694

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 7

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454